Key Takeaway: CalciMedica has reported its financial results for the second quarter of 2026, highlighting a successful private placement financing of approximately $49 million. This funding aims to support the advancement of their pulmonary hypertension program, with proof-of-concept data for Auxora in pulmonary arterial hypertension expected by mid-2027. Additionally, the company anticipates submitting an IND for CM5480 in the same timeframe.
Market Sentiment Analysis
POSITIVE FACTORS
Successful completion of a $49 million private placement financing.
Advancement of the pulmonary hypertension program.
Positive alignment with the FDA on clinical endpoints.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~2 mo
High dilution risk
Lead asset
CM-4620 Injectable Emulsion or CM-4620-IE
Phase 2 · Acute Pancreatitis
Full Press Release Details
Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027 FDA aligned that the primary endpoint for the
Frequently Asked Questions
What financing did CalciMedica complete?
CalciMedica completed a private placement financing of approximately $49 million.
What is the purpose of the financing?
The financing aims to advance CalciMedica's pulmonary hypertension program.
When is the proof-of-concept data expected?
The proof-of-concept data for Auxora is anticipated in mid-2027.
What does FDA alignment entail?
The FDA has aligned with CalciMedica on the primary endpoint for their studies.